Fennec Pharmaceuticals reported ASHA-defined hearing loss in 24.0% of patients in its Japan study, below the prespecified 56.4% historical benchmark, with P=0.001. The result met the primary endpoint and showed no evidence that PEDMARK interfered with cisplatin’s antitumor activity, supporting the company’s Japan registration effort.
Key Highlights
- PEDMARK produced objective tumor responses in 23 of 24 evaluable patients, or 95.8%.
- The study found no higher-grade hearing loss under Brock grading.
- Fennec Pharmaceuticals is pursuing registration in Japan while exploring partnering or licensing opportunities for PEDMARK.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a biotechnology company. On September 17, 2026, the company reported ASHA-defined hearing loss in 24.0% of patients in its Japan study, compared with a prespecified historical benchmark of 56.4% and P=0.001. The primary endpoint was met, with no evidence of interference with cisplatin antitumor activity.
Japan Study Shows Hearing Protection
The primary efficacy population included 25 patients, with 19 remaining free of ASHA-defined hearing loss. That represented 76.0% of the group. The study also found no higher-grade hearing loss under Brock grading. Prospective pharmacokinetic analyses gave mechanistic support to delayed PEDMARK administration after cisplatin, according to the company. The company said it is pursuing registration in Japan and exploring partnering or licensing opportunities for the therapy.
Antitumor Activity Accompanied Hearing Results
Objective tumor responses occurred in 23 of 24 evaluable patients, equal to 95.8%. The company said those findings provided clinical context for delayed PEDMARK administration after cisplatin. Fennec described the results as a significant reduction in hearing loss against the prespecified benchmark. The company said the findings added independent evidence supporting delayed PEDMARK administration.
FAQs
Q: What were the Fennec Pharmaceuticals PEDMARK study results in Japan?
A: Fennec Pharmaceuticals reported that the Japan study met its primary endpoint, with ASHA-defined hearing loss occurring in 24.0% of patients versus a 56.4% historical benchmark.
Q: What was the objective response rate in Fennec’s PEDMARK study?
A: Objective tumor responses were recorded in 23 of 24 evaluable patients, representing 95.8%. The company said this supported the clinical context for delayed PEDMARK administration.
Q: What is Fennec Pharmaceuticals doing next in Japan?
A: Fennec Pharmaceuticals is pursuing registration in Japan for PEDMARK. The company is also exploring partnering or licensing opportunities for the therapy.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.